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ABSTRACT The majority of severe visual loss in the
United States results from complications associated with
retinal neovascularization in patients with ischemic ocular
diseases such as diabetic retinopathy, retinal vein occlusion,
and retinopathy of prematurity. Intraocular expression of the
angiogenic protein vascular endothelial growth factor (VEGF)
is closely correlated with neovascularization in these human
disorders and with ischemia-induced retinal neovasculariza-
tion in mice. In this study, we evaluated whether in vivo
inhibition of VEGF action could suppress retinal neovascu-
larization in a murine model of ischemic retinopathy. VEGF-
neutralizing chimeric proteins were constructed byjoining the
extracellular domain of either human (Flt) or mouse (Flk)
high-affinity VEGF receptors with IgG. Control chimeric
proteins that did not bind VEGF were also used. VEGF-
receptor chimeric proteins eliminated in vitro retinal endo-
thelial cell growth stimulation by either VEGF (P < 0.006) or
hypoxic conditioned medium (P < 0.005) without affecting
growth under nonstimulated conditions. Control proteins had
no effect. To assess in vivo response, animals with bilateral
retinal ischemia received intravitreal injections of VEGF
antagonist in one eye and control protein in the contralateral
eye. Retinal neovascularization was quantitated histologically
by a masked protocol. Retinal neovascularization in the eye
injected with human Flt or murine Flk chimeric protein was
reduced in 100% (25/25; P < 0.0001) and 95% (21/22; P <
0.0001) of animals, respectively, compared to the control
treated eye. This response was evident after only a single
intravitreal injection and was dose dependent with suppres-
sion of neovascularization noted after total delivery of 200 ng
of protein (P < 0.002). Reduction of histologically evident
neovascular nuclei per 6-,um section averaged 47% ± 4% (P <
0.001) and 37% ± 2% (P < 0.001) for Flt and Flk chimeric
proteins with maximal inhibitory effects of 77% and 66%,
respectively. No retinal toxicity was observed by light micros-
copy. These data demonstrate VEGF's causal role in retinal
angiogenesis and prove the potential of VEGF inhibition as a
specific therapy for ischemic retinal disease.
Complications resulting from uncontrolled retinal angiogen-
esis account for most of the severe and irreversible visual loss
associated with ischemic retinal disorders. These disorders
include retinopathy of prematurity, diabetic retinopathy, ret-
inal vein occlusion, and others, together accounting for the
majority of new-onset legal blindness in the United States each
year (1). For nearly one-half century, the retinal ischemia
universally present in these conditions has been thought to
promote the elaboration of angiogenic factors, ultimately
resulting in neovascularization (2, 3). Recently, the molecule
that has been variously referred to as vascular endothelial
growth factor (4), vasopermeability factor (5), and vascu-
lotropin (6) has been shown to possess many properties which
suggest that it may mediate the majority of intraocular neo-
vascularization associated with ischemic retinal disorders.
Vascular endothelial growth factor (VEGF) was originally
described in highly vascularized tumors where its expression is
increased by hypoxia (5, 7-9). VEGF is an endothelial mitogen
(10), angiogenic protein (8-10), and potent vasopermeability
factor (11, 12) that mediates its effects through the endothelial
cell-specific, high-affinity, cell-surface transmembrane recep-
tors fins-like tyrosine kinase (Flt) and fetal liver kinase 1
(Flk-1) (10, 13-15). Unlike molecules such as basic fibroblast
growth factor, VEGF possesses a signal sequence and is
secreted from intact cells (16, 17). In ocular tissues, studies
have demonstrated that VEGF production is increased by
hypoxia in retinal pigment epithelial cells, retinal endothelial
cells, retinal pericytes (15, 18, 19), Muller cells (20), and both
mouse and primate eyes with ischemia-induced retinal (20)
and iris (21) neovascularization, respectively. Retinal endo-
thelial cells possess numerous high-affinity VEGF receptors
(13, 15). Recent clinical studies have demonstrated a close
correlation between active ocular neovascularization and ele-
vated intraocular VEGF concentrations in patients with dia-
betes mellitus, central retinal vein occlusion, retinopathy of
prematurity, and rubeosis iridis (22, 23). However, a require-
ment for VEGF in the retinal neovascular response has not
been proven.
Here we report that VEGF-neutralizing chimeric proteins,
constructed byjoining the extracellular domain of high-affinity
VEGF receptors with the heavy chain of IgG, substantially
reduce the development of retinal neovascularization when
injected into the eyes of mice with ischemic retinal disease.
This inhibition is specific to VEGF-receptor chimeric proteins,
is dose dependent, and occurs in the absence of any histolog-
ically evident ocular toxicity or inflammation. These data
suggest that VEGF serves a causal role in some forms of retinal
angiogenesis. In addition, these studies support the potential of
VEGF inhibition as an innovative therapy for certain ischemic
retinal diseases, thereby circumventing the inherent retinal
destruction produced by current laser photocoagulation and
cryotherapy-treatment regimens (24, 25).
MATERIALS AND METHODS
Cell Cultures. Bovine retinal endothelial cells and retinal
pericytes were isolated from fresh calf eyes by homogenization
and a series of filtration steps as described (26, 27). Primary
Abbreviations: VEGF, vascular endothelial growth factor; P7, etc., post-
natal day 7, etc.
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endothelial cell cultures were grown in fibronectin (NYBen
Reagents, New York Blood Center)-coated dishes (Costar) con-
taining Dulbecco's modified Eagle's medium (DMEM) with 5.5
mM glucose, 10% plasma-derived horse serum (Wheaton, Sci-
entific), 50 mg of heparin per liter and 50 units of endothelial cell
growth factor per liter (Boehringer Mannheim). After the cells
reached confluence, the medium was changed to include 5% fetal
bovine serum (HyClone). Medium was changed every 3 days.
Bovine retinal pericytes were cultured in DMEM/5.5 mM glu-
cose with 20% fetal bovine serum.
Hypoxic Conditioned Medium. Confluent retinal pericyte
monolayers were exposed for 24 hr to 2% 02/5% C02/93% N2
using a Lab-Line Instruments advanced computer controlled
infrared water-jacketed CO2 incubator with reduced oxygen
control (model 480). All cells were maintained at 37°C and
showed no morphologic changes by light microscopy, excluded
trypan blue dye (>98%), and could subsequently be passaged
normally. Cells incubated under normoxic conditions (95%
air/5% C02) from the same batch and passage were used as
controls. Medium was subsequently collected and filtered
(Nalgene; 0.22 gm) prior to use.
Retinal Endothelial Cell Growth Assay. Bovine retinal
endothelial cells were plated sparsely (-2500 cells per well) in
24-well dishes (Costar) overnight in DMEM containing 10%
calf serum (GIBCO). VEGF (25 ng/ml; Genentech) was
added to the medium or the medium was replaced with
conditioned medium the next day in the presence or absence
of a 10-fold molar excess of chimeric protein as indicated in the
text. After incubation at 37°C for 4 days, the cells were lysed
in 0.1% SDS and DNA content was measured using Hoechst
33258 dye and a fluorometer (model TKO-100; Hoefer) (13).
VEGF-Receptor Chimeric Proteins and Controls. Two
VEGF-receptor-IgG chimeric proteins were constructed us-
ing Pfu polymerase and PCR. One molecule contained the
entire extracellular domain (758 residues) of the human high-
affinity VEGF receptor Flt fused to the coding sequence for
amino acids 216-443 of the human IgGyl heavy chain, while
the other contained the entire extracellular domain of the
murine VEGF receptor Flk-I fused to a mouse IgG(y2B)
heavy chain (22, 28). These VEGF-IgG chimeric receptors
have the same affinity for VEGF as full-length VEGF recep-
tors (Kd = 20 pM) and bind free VEGF, preventing it from
effectively interacting with native receptors on vascular endo-
thelial cells. Control chimeric proteins were constructed in a
similar manner using an entirely human CD4-IgG chimera as
control for Flt-IgG and a menoclonal anti-gpl20 antibody of
the same IgG(-y2B) isotype as the murine chimeric protein for
the Flk-1-IgG control. Endotoxin levels were <0.5 unit per mg
of protein for each preparation.
Mouse Model of Ischemia-Induced Retinal Neovasculariza-
tion. This animal model has been described (20, 29). Briefly,
C57BL/6J mice were exposed to 75% 02 from postnatal day
7 (P7) to P12 along with nursing mothers. At P12, the mice
were returned to room air. Intraocular injections were per-
formed at P12 and sometimes P14 as described below. At P17
the mice were sacrificed by cardiac perfusion of 4% parafor-
maldehyde in phosphate-buffered saline and the eyes were
enucleated and fixed in 4% paraformaldehyde overnight at 4°C
before paraffin embedding.
Intraocular Injections. Mice were deeply anesthetized with
tribromoethanol (Avertin) for all procedures. The lid fissure
was opened using a no. 11 scalpel blade and the eye was
proptosed. Intravitreal injections were performed by first
entering the eye with an Ethicon TG140-8 suture needle at the
posterior limbus. A 32-gauge Hamilton needle and syringe
were used to deliver 0.5 ,A of protein solution diluted in Alcon
balanced salt solution through the existing entrance site. The
eye was then repositioned and the lids were approximated over
the cornea. Repeat injections were performed through a
previously unmanipulated section of limbus 2 days later.
Neovascular Quantitation. Over 50 serial 6-,um paraffin-
embedded axial sections were obtained starting at the optic
nerve head. After staining with periodic acid/Schiff reagent
and hematoxylin (20, 29), 10 intact sections of equal length,
each 30 ,tm apart, were evaluated for a span of 300 ,um. Eyes
exhibiting retinal detachment or endophthalmitis were ex-
cluded from evaluation and accounted for <11 % of those
studied. All retinal vascular cell nuclei anterior to the internal
limiting membrane were counted in each section by a fully
masked protocol. The mean of all 10 counted sections yielded
average neovascular cell nuclei per 6-,um section per eye. No
vascular cell nuclei anterior to the internal limiting membrane
are observed in normal, unmanipulated animals (29).
Statistical Analysis. All determinations were performed at
least in triplicate and experiments were repeated a minimum of
three times. Results are expressed as means ± SD for all
experiments. Analysis of in vitro results was performed by non-
paired Student's t test. Analysis of in vivo results used the x2 test
for categorical data and paired Student's t test or the Mann-
Whitney rank sum test for quantitative data with unequal vari-
ance. AP value of <0.050 was considered statistically significant.
RESULTS
Chimeric VEGF-receptor protein effect on VEGF action in
vitro was evaluated by using sparsely plated cultures of bovine
retinal microvascular endothelial cells (13, 26), which undergo
growth stimulation after addition of VEGF (13, 18). Stimula-
tion of these cells with recombinant human VEGF (25 ng/ml)
produced a characteristic 68% ± 1.6% increase in cellular
DNA content after 4 days (P < 0.001) compared with un-
stimulated cells (Fig. 1A). This VEGF stimulatory capacity was
entirely eliminated by simultaneous addition (5 ,tg/ml) of
either human Flt-IgG (P = 0.006) or murine Flk-1-IgG
chimeric protein (P = 0.003) but not by control proteins that
were not directed against VEGF. Similarly, retinal endothelial
cell growth was stimulated 128% ± 10% (P = 0.002) by
conditioned medium from retinal pericytes cultured under
hypoxic conditions known to induce VEGF expression (18).
This growth stimulation was suppressed 89% ± 11% in the
presence of human Flt-IgG at 5 ,ug/ml (P < 0.001) and 82%
+ 12% with addition of murine Flk-1-IgG at 5 jig/ml (P <
0.001), while control proteins had no effect (Fig. 1B).
To evaluate whether VEGF-specific chimeric proteins could
reduce retinal neovascularization in vivo, we used a highly
reproducible murine model of ischemia-induced retinal neo-
vascularization (29). C57BL/6J mice exposed to 75% 02 from
P7 to P12 experience extensive retinal capillary obliteration.
When these mice are returned to room air on P12, the inner
retina becomes relatively hypoxic, VEGF mRNA and protein
levels are increased (20), and retinal neovascularization occurs
in 100% of animals by P17 (29).
Intraocular injection of 200-500 ng of human Flt-IgG or
225-750 ng of murine Flk-1-IgG chimeric protein performed as
the mice were returned to room air reduced histologically evident
retinal neovascularization at P17 in 25 of 25 (100%; P < 0.0001)
and 21 of 22 (95%; P < 0.0001) animals, respectively, compared
with equivalent injection of control protein in the contralateral
eye (Fig. 2). This effect was detectable at total chimera doses of
200 ng and above per eye, even when only a single intravitreal
injection was performed. The magnitude of neovascular suppres-
sion was dose dependent (Fig. 3) with an inhibition of47% ± 4%
(P < 0.001) obtained when a maximally concentrated chimeric
solution of Flt (250 ng) was delivered on both P12 and P14.
Individual animals demonstrated up to 77% inhibition in retinal
neovascularization. Dose-dependent neovascular inhibition was
also observed with a single 225-ng injection of Flk-1-IgG (37%
+ 2%; nine animals; P < 0.001) or a similar dual injection (46%
+ 12%; three animals; P = 0.050; data not shown). Technical
considerations in these neonatal mice precluded testing of more
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FIG. 1. Stimulation of retinal endothelial cell growth by VEGF (A)
or hypoxic-conditioned medium (B) is inhibited by human and mouse
VEGF receptor chimeric proteins. (A) Sparsely plated bovine retinal
endothelial cells were exposed for 4 days to either no VEGF (bars 1-5)
or recombinant human VEGF at 25 ng/ml (bars 6-10) in the presence
of 10-fold molar excess (5 ,ug/ml) of concurrently administered human
Flt-IgG chimera (bars 2 and 7; Flt), human CD4-IgG chimera (bars
3 and 8; CD4), murine Flk-1-IgG chimera (bars 4 and 9; Flk-1), or
anti-gpl20 monoclonal antibody of the same IgG(-y2B) isotype as the
murine Flk-1-IgG chimeric protein (bars 5 and 10; gpl20). DNA
content was measured after cell lysis in 0.1% SDS (13). (B) Condi-
tioned media were collected from retinal microvascular pericytes
cultured under hypoxic conditions (2% 02/5% C02/93% air) at 37°C
for 24 hr (18, 27), filtered, and applied to sparsely plated bovine retinal
endothelial cells for 4 days (bars 2-6) in the presence of human
Flt-IgG chimera (bar 3; Flt), human CD4-IgG chimera (bar 4; CD4),
murine Flk-1-IgG chimera (bar 5; Flk-1), or murine anti-gpl20
monoclonal antibody (bar 6; gpl20). Normoxic pericyte conditioned
medium was used as a control in bar 1. Error bars indicate standard
error of triplicate samples from a representative experiment. Exper-
iments were repeated three times with similar results.
concentrated solutions or more frequent administration. Sup-
pression of the neovascular response was evident by histologic
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FIG. 2. Inhibition of VEGF suppresses neovascularization of isch-
emic mouse retina in vivo. To induce neovascularization, C57BL/6J
mice with nursing mothers were exposed at P7 to 75% oxygen for 5
days and then returned to room air (29). Immediately upon return to
room air, the left eye was injected intravitreally with 100-250 ng of
human Flt-IgG chimera (A) or 225-375 ng of murine Flk-1-IgG
chimera (B), while the right eye was injected with equivalent doses of
either human CD4-IgG chimera or murine anti-gpl20 monoclonal
antibody controls, respectively. Eyes were reinjected on P14 and
enucleated on P17. Average neovascular cell nuclei per 6-,um histo-
logical section per eye were determined as described. Eyes from the
same animal are connected by solid lines, and arrows mark the mean
of each group.
examination of paraffin-embedded ocular cross-sections (Fig.
4). No retinal toxicity or inflammation was apparent by light
microscopy.
DISCUSSION
Our initial data demonstrated that VEGF receptor chimeric
proteins could prevent in vitro stimulation of retinal endothe-
lial cell growth by both exogenous and hypoxia-induced
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FIG. 3. Inhibition of retinal neovascularization is dose dependent on
extent of VEGF inhibition. Retinal neovascularization determined from
neovascular nuclei counts of chimeric treated eyes is expressed as percent
of right eye control for each treatment regimen. Intravitreal injections of
0.5 ,ul each were performed on P12 and P14. Error bars indicate standard
error for all animals in each group. Statistical differences compared with
control eyes are indicated.
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FIG. 4. Soluble VEGF receptor-IgG chimeric proteins reduce histologically evident ischemia-induced retinal neovascularization. Retinal
ischemia was induced in C57BL/6J mice as described in Fig. 2. The right eye of each mouse was injected with 250 ng of human CD4-IgG control
chimeric protein on P12 and P14 (Left). The left eye received intravitreal injections of 250 ng of human Flt-IgG chimera at the same times (Right).
Paraffin-embedded, periodic acid/Schiff reagent, and hematoxylin-stained 6-,um serial sections were obtained as described. Typical findings from
corresponding retinal locations from both eyes of the same mouse are shown and are representative of all animals studied. Vascular cell nuclei
internal to the inner limiting membrane represent areas of retinal neovascularization and are indicated with arrows. No vascular cell nuclei anterior
to the internal limiting membrane are observed in normal, unmanipulated animals (29). (X50.)
VEGF. Since VEGF expression had been closely linked to
active retinal neovascularization in numerous human ischemic
retinal disorders, this finding suggested that these molecules
might be capable of suppressing retinal neovascularization in
vivo. To demonstrate that inhibition of VEGF is sufficient to
reduce retinal neovascularization in vivo, we have used a highly
reproducible murine model of ischemia-induced retinal neo-
vascularization (29). During hyperoxic exposure, these neona-
tal mice experience extensive retinal capillary obliteration.
When they are returned to room air, the inner retina becomes
relatively hypoxic, VEGF mRNA and protein levels are in-
creased (20), and retinal neovascularization occurs in 100% of
animals (29). Thus, this mouse model resembles retinopathy of
prematurity, which occurs in prematurely born human infants
in whom the retina is incompletely vascularized, presumably
resulting in ischemia, VEGF induction, and retinal neovascu-
larization (22, 25). In addition, the VEGF elevation and
increase in vascular permeability observed in the mouse model
resemble these same characteristic findings observed in pro-
liferative diabetic retinopathy and other ischemic retinal dis-
orders (22).
Our results demonstrate that soluble VEGF-binding chi-
meric proteins can reduce ischemia-induced retinal neovascu-
larization in vivo without discernible short-term retinal toxic-
ity. Thus, VEGF appears to be important for development of
ischemia-induced retinal angiogenesis. Since VEGF levels
increase in these disorders (20-22), it appears that VEGF
could be one of the direct causative factors for clinically
observed neovascularization in certain ischemic retinal dis-
eases.
The finding that '50% of retinal neovascularization was not
inhibited by anti-VEGF treatment could imply that other
angiogenic substances account for the remaining stimulatory
activity.- However, the large chimeric proteins used in these
studies would not be expected to diffuse into the retinal tissues,
thus limiting their inhibitory effects to that portion of VEGF
secreted into the vitreous fluid, which subsequently acts on the
retinal capillaries on the inner retinal surface. VEGF, how-
ever, is secreted within the substance of the retina (20) and
certain isoforms are freely diffusible (17). Thus, activity of
intraretinal VEGF may not be inhibited by intravitreal injec-
tion of chimeric proteins and could account for the remaining
angiogenic activity. In larger eyes, the potential for delivery of
more concentrated solutions or more frequent administration
of inhibitors might further reduce neovascular activity.
Current clinical treatment for active intraocular neovascu-
larization involves destruction of peripheral retinal by either
laser scatter photocoagulation (24, 30) or cryotherapy (25).
The beneficial effect is presumably mediated by relatively
improved perfusion resulting from the same blood flow to less
remaining viable retina and by increased diffusion of oxygen
from the choroid to the inner retina through thinned retinal
scars (31). Although often effective, these procedures induce
multiple side effects because of their inherently destructive
nature, including decreased peripheral vision, poor night
vision, and impaired color perception (24). In addition, the
disease processes may progress despite timely and exhaustive
therapy (24, 25). The findings presented here suggest that
inhibitors of VEGF action may be used to prevent some types
of intraocular neovascularization without the retinal destruc-
tion inherent in current therapeutic modalities.
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